Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

ImmunoPrecise Names Dr. Dion Neame to Strategic Advisory Board

IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Dion Neame has joined the company’s Strategic Advisory Board (SAB). Dr. Neame joins at a significant time, as the company continues to focus its energy on building essential partnerships and expanding its rapidly growing share of the market. He will play a key role in supporting the strategic and scientific prioritization of partnerships and stakeholder communications.

Dr. Neame is a clinical medicine and vaccine expert, focused on medical strategies for various indications and early pipeline products, as well as external medical and scientific stakeholder engagements.

With over 15 years’ experience in large pharma, Dr. Neame has held many impressive leadership roles, including North American Senior Medical Expert and Country Medical Lead, Canada. He also has extensive experience as a medical professional, including pediatric medicine at notable hospitals such as McMaster Children’s Hospital and as Chief of Pediatrics Joseph Brant Hospital in Ontario, Canada.

“The addition of Dr. Neame to our SAB is instrumental in helping to bring IPA to the next level of growth and strategic execution,” noted Dr. Jennifer Bath, ImmunoPrecise’s CEO. “His scientific expertise in translational research, medical governance and compliance standards, combined with his expertise in stakeholder engagement, will play an important role as we execute on our strategic plans. It is wonderful to have someone with Dr. Neame’s breadth and depth of experience - from both a business and scientific perspective - to join us at this exciting moment for IPA.”

Dr. Neame, the 2020 recipient of the Innovative Medicines Respected Partner Award, who also serves as a consulting pediatrician, has concurrently held the position of Assistant Clinical Professor at McMaster University (Hamilton, Ontario) in the Department of Pediatrics for over 20 years. Throughout his career, Dr. Neame has contributed to numerous vaccine research programs and has been instrumental in establishing the medical, scientific and health economic rationale for 16 new vaccination programs in provinces and territories across Canada.

“I look forward to joining ImmunoPrecise’s Strategic Advisory Board,” stated Dr. Neame. “We are living in turbulent times and the need for novel therapeutic antibodies with broad epitope coverage has never been more important, to compliment COVID-19 vaccines to control SARS-CoV-2 variants of concern. IPA is a world-class Contract Research Organization (CRO), rich in science and housing cutting-edge antibody platform technologies. The Company’s custom approaches enable multiple antibody pathways, providing agile and adaptable discoveries to match agile and adaptable infectious microorganisms, as showcased in their work targeting SARS-CoV-2.”

ImmunoPrecise Antibodies Ltd.

IPA is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. The Company aims to transform the conventional, multi-vendor, product development model by bringing innovative and high-throughput, data-driven technologies to its partners, incorporating the advantages of diverse antibody repertoires with the Company’s therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple/rare epitopes. For further information, visit www.immunoprecise.com or contact solutions@immunoprecise.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.